Clinical trial · Observational
The PROMISE Survey
Patients' and Physicians' Perspectives on the Management of Prolactinomas: Experiences, Treatment Preferences, and Related Outcomes - The PROMISE Survey
NCT06936813CI-TRIAL-00100470active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The PROMISE Survey was developed to systematically assess the real-world experiences, treatment preferences, side effects, and outcomes from both patients and physicians dealing with prolactinomas. The aim is to generate insights that can guide future clinical research and improve individualized care strategies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pituitary Tumor | Pituitary Gland Neoplasm | ALIAS | 0.90 |
| Prolactinoma | Lactotroph Pituitary Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Generate hypotheses for future research
- timeFrame
- 6 months
- description
- Generate real-world patient-centered data to identify patterns in treatment outcomes, patient-reported challenges, and areas where additional clinical trials are needed to develop new hypothesis for future research
Secondary outcomes (7)
- measure
- Collect data on patient characteristics
- timeFrame
- 6 months
- description
- Distribution of patient demographics, cause of prolactinoma, additional pituitary disfunctions, symptom burden before diagnosis
- measure
- Assess patient experiences with dopamine agonist (DA) therapy
- timeFrame
- 6 months
- description
- Distribution of DA types and dosing, side effects, remission
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prolactinoma patients * Prolactinoma treating physicians including endocrinologists and neurosurgeons
References
Publications (0)
Data not yet available
No reference posted for this study.